Garrett Ruth, MD
Interventional Cardiology · West Columbia, SCNPI 1174943278
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Abbott at 39.1% of the total. Reporting peaked in 2020 at $6,489 and has fallen 78.8% since, to $1,376 in 2025.
Across 324 payments — averaging $41.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$2K
- Novartis$1K
- Inari Medical, Inc.$543
- Boston Scientific$461
- Pfizer$428
- plus $3K from 29 others
What the payments were for
- Grants$4,75035%
- Travel & lodging$1,1378%
- Food & beverage$7,43455%
- Education$2102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 10 | $5,289 |
| Medtronic(2 entities) | 30 | $2,445 |
| Novartis | 92 | $1,383 |
| Inari Medical, Inc. | 9 | $543 |
| Boston Scientific | 7 | $461 |
| Pfizer | 27 | $428 |
| Abiomed | 4 | $388 |
| Stryker | 32 | $360 |
| Amgen | 21 | $343 |
| Merck | 13 | $223 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $179 |
| Penumbra, Inc. | 5 | $165 |
| Alnylam Pharmaceuticals Inc. | 7 | $152 |
| E.r. Squibb & Sons, L.L.C. | 10 | $148 |
| Shockwave Medical, Inc | 2 | $105 |
| Cardiovascular Systems Inc. | 3 | $105 |
| AstraZeneca | 7 | $104 |
| Esperion Therapeutics, Inc. | 5 | $86 |
| Bayer | 5 | $86 |
| Johnson & Johnson | 5 | $71 |
| Bridgebio Pharma, Inc. | 3 | $57 |
| Lexicon Pharmaceuticals, Inc. | 3 | $56 |
| Boehringer Ingelheim | 3 | $54 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Kestra Medical Technology Services, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Philips North America LLC | 1 | $26 |
| Novo Nordisk | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Cordis US CORP. | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Artivion, Inc. | 1 | $13 |
| Cashflow Solutions, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$1,312
- FLOWTRIEVER CATHETER, S$419
- CT THROMBECTOMY SYSTEM KIT$419
- Impella$230
- HeartMate 3 Left Ventricular Assist Device$210
- ONYX FRONTIER$154
- SYMPLICITY G3$151
- COMET$141
- FlowTriever$140
- AVVIGO Guidance System$129
- Optis Coronary Imaging System$120
- Absolute Pro vascular stent system$110
- Resolute$104
How this compares
$13,532 in reported general payments places this provider in the 60th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 270 | $259,403 |
| EntrestoSacubitril/Valsartan | 88 | $76,394 |
| Repatha SureclickEvolocumab | 49 | $37,451 |
| BrilintaTicagrelor | 49 | $28,079 |
| XareltoRivaroxaban | 23 | $28,063 |
| JardianceEmpagliflozin | 23 | $22,186 |
| Metoprolol Succinate | 265 | $3,683 |
| Atorvastatin Calcium | 204 | $3,149 |
| Rosuvastatin Calcium | 177 | $2,415 |
| Carvedilol ErCarvedilol Phosphate | 11 | $2,131 |
| Clonidine | 12 | $1,711 |
| Amiodarone Hcl | 49 | $1,521 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 42 | $1,350 |
| Carvedilol | 113 | $1,055 |
| Losartan Potassium | 76 | $1,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $428 | $259,403270 claims |
| NovartisEntresto | $1,383 | $76,39488 claims |
| AstraZenecaBrilinta | $104 | $28,07949 claims |
| Johnson & JohnsonXarelto | $71 | $28,06323 claims |
| Boehringer IngelheimJardiance | $54 | $22,18623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in West Columbia
- Robert LeonardiWest Columbia$203K
- Christopher PerryWest Columbia$26K
- Robert MalanukWest Columbia$25K
- Gregory GiuglianoWest Columbia$25K
- Jonathan HewettWest Columbia$11K
- Brandon DraftsWest Columbia$11K
- William BrearleyWest Columbia$10K
- Brian WallWest Columbia$10K
- Daniel SteinbergCharleston$611K
- Brian BrownSpartanburg$389K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.